Eric Lawitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eric lawitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eric Lawitz Today - Breaking & Trending Today

UPDATE – Galectin Therapeutics to Present Six Scientific

New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic. ....

Naga Chalasani , Eric Lawitz , Andrea Mladenovic , Archita Parikh Desai , Stephena Harrison , D Harold Shlevin , Raj Vuppalanchi , Pol Boudes , Barbara Lomeli , Harold Shlevin , Nagap Chalasani , Zachary Goodman , Eliezer Zomer , Khim Chng , Juan Rondon , Mazen Noureddin , International Study Evaluating The Efficacy , Nuclear Magnetic Resonance , Galectin Therapeutics Inc , Liver Cirrhosis , Artificial Intelligence , Liver Meeting , American Association , Liver Diseases , Chief Medical Officer , Non Alcoholic Fatty Liver Disease ,

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

Share this article
Share this article
CUPERTINO, Calif., June 9, 2021 /PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021
The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall improvement from baseline observed in liver enzymes, serum lipid profiles, liver fat by imaging, and biomarkers of liver health. The poster will feature additional efficacy signal data including liver stiffness by transient elastography (TE) and magnetic resonance elastography (MRE), liver fibrosis marker, pro-C3, and ELF scores, as well as insulin resistance (HOMA-IR). ....

United States , Eric Lawitz , Jaymin Shah , Texas Liver Institute , Drug Administration , International Liver Conference , Corporation Nasdaq , Research Development , Liver Conference , Presentation Details , Week Oral , Vice President , Texas Liver , Executive Director , Clinical Pharmacology , Fast Track , Boxed Warning , Looking Statement , Durect Corporation , ஒன்றுபட்டது மாநிலங்களில் , ஜெய்மின் ஷா , டெக்சாஸ் கல்லீரல் நிறுவனம் , சர்வதேச கல்லீரல் மாநாடு , நிறுவனம் நாஸ்டாக் , ஆராய்ச்சி வளர்ச்சி , ப்ரெஸெஂடேஶந் விவரங்கள் ,